Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

COVID-19

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Hopital Henri Mondor, Créteil, France
Contact: Study coordinator (Jean Daniel Lelièvre, MD)
Hôpital Cochin, Paris, France
Contact: Study coordinator (Odile Launay, MD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Immunity and Safety of Covid-19 Synthetic Minigene Vaccine

Pathogen Infection Covid-19 Infection

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shenzhen, China

Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants

SARS-CoV-2 (COVID-19)

Abroad (travel likely)RecruitingPHASE1

London, United Kingdom · London, United Kingdom

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

COVID-19

Abroad (travel likely)RecruitingPHASE1

Decatur, United States · Baltimore, United States

The Impact of COVID-19 on Maternal and Neonatal Outcomes

COVID-19 · Pregnancy; Infection

Abroad (travel likely)Recruiting

Baltimore, United States